China Orders Stepped-Up Oversight Of Heparin Production
This article was originally published in PharmAsia News
Executive Summary
China's State FDA has ordered increased supervision and inspection of drug makers producing the blood thinner heparin. The order went out to FDA bureaus around the country to make sure companies follow regulations while producing the material. Bureau chiefs are to make sure producers obtain raw heparin only from registered suppliers and the suppliers in turn strengthen their own oversight of raw and supplementary materials. Drug makers also are being advised to track production carefully and recall any product that has possible safety problems. (Click here for more